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(p = 0.26); and olanzapine vs. risperidone 1.084 (p =
0.87). Furthermore, adjusted odds ratios of being treated
with a lipid-lowering agent were: atypical vs. typical
1.553 (p = 0.46); risperidone vs. typical 1.711 (p = 0.42);
olanzapine vs. typical 1.474 (p = 0.55); and olanzapine
vs. risperidone 0.775 (p = 0.66). CONCLUSION: Based
on a claims database, 1-year incidence of hyperlipidemia
was generally comparable in schizophrenia patients
receiving treatment with typical antipsychotics, olanzap-
ine or risperidone, though typical-treated patients had
numerically lower incidence compared to those atypical-
treated patients.
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OBJECTIVES: To investigate the association between
sexual dysfunction and nonadherence with antipsychotic
therapy in individuals with schizophrenia. METHODS:
In June 2001, 842 individuals with schizophrenia com-
pleted a self-administered questionnaire that included
questions about the side effects of antipsychotic therapy.
Respondents rated frequency of sexual dysfunction as 
a medication side effect, as well as the degree of dis-
tress and general satisfaction with sexual health and
sexual relationships. Therapeutic nonadherence (non-
compliance) was scored by the self-reported frequency of
missed or skipped antipsychotic doses in an average week.
The association between sexual dysfunction and adher-
ence was evaluated through bivariate analysis and a mul-
tivariate linear regression model, which included Drug
Attitude Inventory (DAI) scores, demographic factors,
and the use of other classes of psychotropic medications.
RESULTS: Among self-reported side effects, distress from
sexual dysfunction was very common. It proved second
only to weight gain in the degree of distress reported by
respondents. A negative association was also found
between reported sexual dysfunction and satisfaction
with sexual health and sexual relationships (P < 0.001).
Sexual dysfunction was associated with self-reported 
nonadherence, both in bivariate analysis (P = 0.024) and
multivariate linear regression (P = 0.035). CONCLU-
SION: In this survey, sexual dysfunction was associated
with reduced adherence to antipsychotic therapy. These
data underscore the importance of assessing side 
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OBJECTIVE: To evaluate sample differences associated
with recruiting strategies in a study of people with 
schizophrenia. METHODS: In June 2000 and 2001, 
participants were identiﬁed through Community Mental
Health Centers (CMHC) and chapters of the National
Alliance for the Mentally Ill (NAMI) for a study designed
to understand, explain, and predict the healthcare 
attitudes and behaviors of people with schizophrenia.
Data were collected using self-administered question-
naires. RESULTS: As expected, CMHC (n = 416) and
NAMI (n = 430) respondents differed demographically.
CMHC respondents were more likely to be older (p <
0.001), non-white (p = 0.002), living in group homes (p
< 0.001), and concentrated in urban regions of the
country (Northeast and West, p < 0.001). CMHC respon-
dents were less likely than NAMI recruits to participate
in productive activities (p < 0.001). However, respondents
from both facilities had similar health histories. They
experienced schizophrenia symptoms for similar dura-
tions and had similar symptom severity, as measured by
the Psychological General Well-Being (PGWB) scale. The
two groups were also equally as likely to be overweight
or obese, diagnosed with high cholesterol, and to use
alcohol. CMHC and NAMI respondents also had similar
patterns of care. They were equally as likely to have been
hospitalized in the past six months and to be insured by
Medicaid. Most respondents from both groups were
treated with atypical antipsychotics and received mental
healthcare from community mental health centers. The
groups had almost identical attitudes about medication
compliance (p = 0.989), as measured by the Drug Atti-
tude Inventory (DAI). They also had similar medication
compliance behaviors; 32% of CMHC recruits and 38%
from NAMI organizations reported at least occasionally
missing their psychotropic medication (p = 0.118). 
CONCLUSION: Despite large demographic differences
between respondents recruited through NAMI and
CMHC, there were few differences in health history, and
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OBJECTIVES: The objective of this study was to assess
the compliance and treatment satisfaction with risperi-
done in a U.S. sample of patients with bipolar disorder.
METHODS: In June 2001, 573 persons reported being
diagnosed with bipolar disorder on a self-administered
questionnaire. Patients receiving risperidone were identi-
ﬁed and information on compliance and treatment satis-
faction was extracted. Satisfaction and compliance with
treatment were measured using the Drug Attitude 
Inventory (DAI) and a 5-point Likert scale. The satisfac-
tion scale ranges from not at all (1) to extremely satisﬁed
(5), while the DAI classiﬁes the patients in 3 groups, non-
compliant (-10 to 0), somewhat compliant (1 to 5), and
very compliant (6 to 10) with treatment. RESULTS:
Thirty-one (5.4%) of 573 patients with bipolar disorder
were receiving risperidone. The average length of treat-
ment was 33.1 (SD = 23.5) months. Twenty-three (73%)
of 31 patients reported being very or extremely (4 or 5)
satisﬁed with the medication, while only 4 patients (12%)
reported no or little satisfaction with treatment. The
majority of patients, 22 (68%), reported being very 
compliant with their treatment. CONCLUSION: In this
population of patients with bipolar disorder, patients
receiving risperidone appear to have a high satisfaction
with treatment and a high compliance rate.
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OBJECTIVE: Compliance plays a major role in chronic
conditions to help achieve a full course of therapy. All
chronic diseases have adherence to prescribed drug
therapy as obstacles to treatment. Potential consequences
of non-adherence include relapse, treatment resistance,
suicide, impairment of functioning (work, interpersonal)
and worsening of comorbid illnesses. All of these poten-
tial consequences can have a signiﬁcant economic burden
on the society. So we intended to evaluate the clinical efﬁ-
cacy of ﬂuoxetine 180mg (2 ¥ 90mg tablets) once a week
in ambulatory patients stabilized on Fluoxetine 40mg
daily. METHOD: Thirty patients stabilized on ﬂuoxetine
40mg daily were evaluated in a mirror image design.
They were switched to ﬂuoxetine 180mg (2 ¥ 90mg
tablets) once a week. Steady state serum drug concentra-
tion and Clinical Global Impression-Severity (CGI-S),
medication compliance and patient attitude survey were
obtained before and after the switch. RESULTS: Mean
age of the patients was 41.7 + 11.7 years, with 8 males
and all of them met DSM IV criteria for major depres-
sion. Mean duration of depression was 8 + 3 years. 
Fluoxetine/Norﬂuoxetine serum concentrations were 261
+ 185 and 295 + 206ng/ml (P = .21.). CGI-S was 2.5 +
0.7 and 2.6 + 0.7 before and after the switch. Compli-
ance before the switch was 73.6% before and 91% after
the switch. This difference was statistically signiﬁcant at 
p < 0.0001 (t = -7.8651, df = 29). 41% of the patients
strongly agreed that weekly dosing regimen was preferred
over daily regimen. CONCLUSION: Our evaluation 
indicates that once a week dosing is as equally clinically
efﬁcacious as a daily dose in the management of major
depression in our population of ambulatory patients. 
Signiﬁcant improvement in compliance can only have a
positive impact on the health outcome and costs.
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OBJECTIVES: To examine and describe gender differ-
ences in psychoactive medication treatment for AD/HD
in a population-based cohort. METHODS: Medical 
and school records of all children born (N = 5718) in
Rochester, MN 1976–1982 were reviewed to identify
those with AD/HD (N = 375). All psychoactive 
medications (psychostimulants [STIM], centrally acting 
alpha-adrenergic agonists [CAA] and/or tricyclic 
antidepressants [TCA]), doses prescribed, start and 
stop dates, and subtype of AD/HD clinical diagnosis 
were abstracted. Psychostimulant doses were converted 
to Methylphenidate Equivalent Units (MEU: 20mg
methylphenidate = 10mg dextroamphetamine = 10mg
amphetamine salts = 56.25mg pemoline). RESULTS:
Boys with AD/HD were more likely than girls to be
treated with STIM, either alone or in combination with
TCA and/or CAA (80.8% vs 69.1%, OR 1.9, 95% CI
1.1–3.2, p = 0.020). However, boys and girls were equally
likely to be treated with STIM alone (66.2% versus
63.8%, OR 1.1, 95% CI 0.7–1.8, p = 0.68). Mean age at
treatment onset was similar (boys 10.3 years, girls 10.7
years, p = 0.46). Median treatment duration was 34
months (mean = 42.0, SD = 37.1), with no gender differ-
ence. Median average daily dose of STIM was 21.3mg
MEU (mean = 24.4mg, SD = 11.0mg). Boys received 
signiﬁcantly higher average daily doses than girls (median
22.5 vs. 20.0mg MEU; p = 0.002). Treatment started 
signiﬁcantly earlier for combined (9.7 years) and 
hyperactive-impulsive subtypes (10.0 years) than for the
inattentive type (12.7 years). Treatment duration was 
signiﬁcantly longer for combined (40.5 months) than for
either hyperactive-impulsive (22.6 months) or inattentive
subtype (19.1 months). The gender differences in AD/HD
treatment described above could not be accounted for by
gender differences in AD/HD subtype. CONCLUSIONS:
Boys with AD/HD were more likely to be treated with
